Please login to the form below

Fycompa

This page shows the latest Fycompa news and features for those working in and with pharma, biotech and healthcare.

Eisai did likewise for its epilepsy treatment Fycompa (perampanel).

Eisai establishes neuroscience unit in Belgium and Luxembourg

The new unit will market the company's epilepsy drug Fycompa (perampanel), which it has been giving a rolling launch across the region. ... Fycompa indicated for the adjunctive treatment of partial onset seizures, with or without secondarily generalised
Eisai opens first office in Australia

Eisai opens first office in Australia. New Melbourne base to support marketing of Halaven and Fycompa. ... Fycompa is the first in a new class of treatment for partial onset seizures, the most common form of epilepsy.
Eisai "speechless" as G-BA denies price premium for Fycompa

Eisai "speechless" as G-BA denies price premium for Fycompa. But company has better news on cancer drug Halaven. ... Eisai's efforts to secure favourable pricing for its epilepsy drug Fycompa in Germany have hit the buffers once again.
Eisai backs competition to find star of epilepsy comic book

Epilepsy is a relative new area of focus for Eisai, whose treatment options include Fycompa (perampanel), which was launched in Europe in 2012.
Eisai ‘outraged’ by IQWIG’s failure to back epilepsy drug

Eisai has issued a damning statement criticising Germany's healthcare watchdog IQWIG for not backing epilepsy drug Fycompa. ... IQWIG's recommendation will now be considered by the G-BA, which is expected to published a decision on Fycompa's use in

More from news
Approximately 13 fully matching, plus 11 partially matching documents found.

Eisai: Bucking the trend with R&D growth

by adding a new solid dose global manufacturing line for its anti-epileptic medicine Fycompa. ... Fycompa was the first Eisai-developed epilepsy drug and it's “ a drug we can really differentiate”, says Hendler.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Lead Medical Copywriter, Healthcare Brand Communications, London: Excellent package

Senior Account Manager / Account Director - Med Comms: Great salary and benefits

Senior/ Market Access Consultant, UK, HOME BASED, £50-60K: Excellent package

Account Director - Award Winning Healthcare Advertising Agency -...: £50000 - £68000

Scientific Director – Medical Communications - New York or Remot...: $100000 - $150000

Add my company

At Swordfish Advertising, we believe building an effective brand shouldn't be stressful. Don't get us wrong; it takes blood, sweat...

Alnylam’s big moment: bringing groundbreaking RNAi drugs to Europe: Theresa Heggie talks about the biotech’s 16-year path to market, and the promise of its ‘gene silencing’ medicines...
Retaining reader value in plain language summaries of clinical studies: Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?: Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...